deal-tracker

name	deal-tracker
description	Track pharmaceutical M&A, licensing, and investment deals. Use for competitive intelligence, market analysis, and identifying partnership opportunities. Keywords: deals, M&A, licensing, partnership, collaboration, acquisition, pharma deals
category	Business Intelligence
tags	["deals","manda","licensing","partnership","investment"]
version	1.0.0
author	Drug Discovery Team
dependencies	["sec-filings","press-releases","deal-databases"]

Deal Tracker Skill

Track pharmaceutical industry deals, M&A, and partnerships.

Quick Start

/deals --oncology --year 2024
/partnership --type licensing --target "EGFR"
/ma-summary --biotech --threshold 100M

What's Included

Section	Description	Source
Deal Feed	Recent announcements	Press releases, SEC
M&A Tracker	Acquisitions and mergers	SEC 8-K, 10-K
Licensing Deals	In-licensing, out-licensing	Company announcements
Partnerships	R&D collaborations	Press releases
Investment	Venture capital, IPO	SEC, exchanges

Output Structure

# Deal Tracker: Oncology Targets (2024)

## Summary
| Metric | Count | Total Value |
|--------|-------|-------------|
| Total Deals | 127 | $45.2B |
| M&A | 12 | $28.5B |
| Licensing | 89 | $14.3B |
| Partnerships | 26 | $2.4B |

## Recent Deals (Last 30 Days)

### M&A
| Date | Acquirer | Target | Value | Type |
|------|----------|--------|-------|------|
| 2024-12-15 | Pfizer | Seagen | $43B | Acquisition |
| 2024-12-10 | BMS | Mirati | $4.8B | Acquisition |

### Licensing
| Date | Licensee | Licensor | Asset | Upfront | Milestones |
|------|----------|---------|-------|---------|------------|
| 2024-12-08 | AstraZeneca | Hengrui | KRAS G12D | $100M | $800M |
| 2024-12-05 | Merck | Daiichi Sankyo | ADC platform | $300M | $1.5B |

## By Target Class

| Target | Deals | Total Value | Avg Upfront |
|--------|-------|-------------|-------------|
| EGFR | 8 | $1.2B | $85M |
| KRAS | 12 | $2.8B | $120M |
| HER2 | 6 | $950M | $78M |

## By Deal Type

| Type | Count | Total Value | Trend |
|------|-------|-------------|-------|
| Acquisition | 12 | $28.5B | ↑ |
| Asset purchase | 45 | $8.2B | → |
| Platform license | 28 | $5.1B | ↑ |
| Co-development | 18 | $1.8B | → |
| Option agreement | 24 | $2.1B | ↓ |

## Key Observations
1. **M&A resurgence**: 12 biotech acquisitions in H2
2. **ADC momentum**: Antibody-drug conjugates dominate
3. **Early-stage focus**: 60% of deals at preclinical/Phase 1
4. **Oncology dominance**: 70% of deal value in oncology

Deal Types

Type	Description	Typical Structure
Acquisition	Full company buyout	Cash + stock
Asset Purchase	Specific asset(s)	Upfront + milestones
Licensing	Rights to develop/sell	Upfront + royalties + milestones
Co-development	Joint development	Cost/revenue sharing
Collaboration	R&D partnership	Funded research
Option	Right to acquire later	Option fee + exercise price
Spin-off	Company separation	Share distribution

Valuation Ranges

Stage	Typical Upfront	Total Deal
Preclinical	$10-50M	$100-500M
Phase 1	$30-100M	$200-800M
Phase 2	$50-200M	$500M-2B
Phase 3	$100-500M	$1B-5B
Approved	$200M-2B	$2B-10B+

Running Scripts

# Recent deals feed
python scripts/deal_tracker.py --feed --days 30

# Filter by target
python scripts/deal_tracker.py --target EGFR --include licensing,manda

# Deal summary
python scripts/deal_tracker.py --summary --year 2024 --oncology

# Export to CSV
python scripts/deal_tracker.py --export --format csv --output deals.csv

Requirements

pip install requests beautifulsoup4 pandas

Reference

• reference/deal-sources.md - Deal data sources
• reference/deal-structures.md - Deal structure reference
• reference/valuation-methods.md - Valuation methodologies

Best Practices

1. Verify from multiple sources: Cross-check deal values
2. **Track milestones: Monitor deal progression
3. Understand structure: Upfront vs milestones vs royalties
4. Compare benchmarks: Similar deals for reference
5. Monitor regulatory: FTC approval may be required

Common Pitfalls

Pitfall	Solution
Misreported values	Check SEC filings
Confusing announced vs closed	Track closing conditions
Ignoring milestones	Total value often optimistic
Currency confusion	Note USD vs local
Double counting	Verify unique deals

Limitations

• Private deals: Terms often undisclosed
• Delayed reporting: SEC filings lag announcements
• Incomplete milestones: Many undisclosed
• Value estimates: Some values are estimates
• Geographic bias: US deals better covered